Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Listen to this Bulletin
- Q2 2026 Federal Psychedelic Lobbying Update
- DEA Revives Bid to Schedule Five Tryptamines
- Advocates Declare Victory as Oregon Shelves Psilocybin Fee Hike
- Stanford, UCSF Researchers Call for "More Aggressive" Blinding in Psychedelic Trials
- BetterLife Raises $100M to Advance Non-Hallucinogenic Candidate in Headache Disorders
- Other Headlines
Q2 2026 Federal Psychedelic Lobbying Update
Now that federal lobbying data from the second quarter of the year is available to retrieve, we present our regular update on the state of activity across psychedelic drug developers and nonprofits.
Psychedelics companies’ spending on lobbying firms at the federal level reached new heights in Q2 2026, though the aggregate amount (just shy of $350,000) remains relatively modest compared to healthcare and pharmaceutical sector lobbying trends.
That spend is driven in large part by Compass Pathways and Definium Therapeutics, which ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In